TGFBI and glioblastoma: For example, scRNA-Seq data analysis demonstrates that GBM tumors from Ccr2-knockout mice harbor a reduced TAM subpopulation with macrophage signatures (e.g., TGFBI, CLEC12A, and FXYD5), but an increased subpopulation with microglia signatures (e.g., SALL1, TMEM119, and P2RY12) (24), suggesting that the antitumor effect of CCR2 inhibition can be attenuated by increased microglia.